Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.CytoCore, a developer of screening systems used for the detection of cancerous and precancerous conditions, has reached an agreement with Amsino International, a developer and manufacturer of disposable medical devices, designating it as the company's partner for worldwide sales.
Subscribe to our email newsletter
Under the agreement, Amsino will direct worldwide sales of CytoCore’s SoftPAP cervical cell collector kits through its channel of distribution partners. Where applicable, such as China, Amsino will sell CytoCore’s products directly to laboratories, and physicians and other medical providers through its direct sales force.
Pursuant to the terms of the agreement, Amsino will be responsible for transportation and warehousing logistics, order management, customer service, quality assurance and bill collection.
According to CytoCore, the SoftPAP cervical cell collector kit offers quicker, more accurate specimen collection with minimal possibility of user error. It is designed to consistently sample the entire cervix in a single-step using an inflatable balloon collector. The results of the clinical trial, conducted by CytoCore and announced in October 2008, demonstrated that sampling in this manner improves the sensitivity and specificity of the diagnosis.
Robert McCullough Jr, CEO of CytoCore, said: “This agreement with Amsino will significantly enhance SoftPAP’s presence in the market and help generate increased sales. We look forward to working with Amsino to explore opportunities to leverage additional areas of their expertise with regard to CytoCore’s present and future product lines.”